Exact Sciences Corporation reported record financial results for the fourth quarter (Q4) and full year (FY) 2025. Total revenue for Q4 2025 reached USD 878 million, representing a 23 percent increase. Screening revenue for the quarter was USD 695 million, while Precision Oncology revenue totaled USD 183 million. For the full year 2025, total revenue was USD 3.25 billion, up 18 percent. Screening revenue contributed USD 2.53 billion, and Precision Oncology revenue was USD 717 million. Operating cash flow for FY 2025 was USD 491 million, and free cash flow stood at USD 357 million, marking a multiple increase compared to the previous year. The company reported a net loss of USD 208 million for FY 2025. Adjusted EBITDA for the year was USD 400 million, with an adjusted EBITDA margin of 12 percent. Product and corporate highlights for the period include the recognition of USD 7.5 million in sublicense revenue under a new agreement executed in Q2 2025, related to technology licensed from TwinStrand BioSciences, Inc. in the third quarter of 2024. The company also completed the divestiture of the Oncotype DX Genomic Prostate Score test, which ceased generating revenue after a transition period in the third quarter of 2024.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EXACT Sciences Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202602131605BIZWIRE_USPR_____20260213_BW963431) on February 13, 2026, and is solely responsible for the information contained therein.
Comments